A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (233 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: subject hasulnthe subjectsubject isms
  Phrases that lowered it: single dosedayoralthe pharmacokineticsreference
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3.3% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports marked serious: 44.4% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 1.4% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 19 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 3 (lowers risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor's past trials: 61 (lowers risk) · Sponsor's track record
• Maximum age: 11 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 2429 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder NCT02211846 · started 2014 · scored riskier than 7% of active trials completed
• Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity NCT02751931 · started 2016 · scored riskier than 21% of active trials completed
• Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder NCT02468830 · started 2013 · scored riskier than 64% of active trials completed
• Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder NCT02476175 · started 2013 · scored riskier than 62% of active trials completed
• A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) NCT04641975 · started 2021 · scored riskier than 19% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.